{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T13:19:31Z","timestamp":1789651171586,"version":"4.0.0"},"reference-count":151,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001409","name":"India Ministry of Science & Technology Department of Science and Technology","doi-asserted-by":"publisher","award":["DST\/INSPIRE Fellowship\/2019\/IF190663"],"award-info":[{"award-number":["DST\/INSPIRE Fellowship\/2019\/IF190663"]}],"id":[{"id":"10.13039\/501100001409","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001843","name":"Science and Engineering Research Board","doi-asserted-by":"publisher","award":["CRG\/2018\/000458"],"award-info":[{"award-number":["CRG\/2018\/000458"]}],"id":[{"id":"10.13039\/501100001843","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["52\/22\/2020-BIO\/BMS"],"award-info":[{"award-number":["52\/22\/2020-BIO\/BMS"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["45\/40\/2022-DDI\/BMS"],"award-info":[{"award-number":["45\/40\/2022-DDI\/BMS"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.drudis.2024.103974","type":"journal-article","created":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T23:03:10Z","timestamp":1711666990000},"page":"103974","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Immunotherapy: An emerging treatment option for neurodegenerative diseases"],"prefix":"10.1016","volume":"29","author":[{"given":"Abhiyanta","family":"Mukherjee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soumojit","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1120-444X","authenticated-orcid":false,"given":"Ipsita","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2024.103974_b0005","series-title":"Immunology \u2013 A Novel Facet of Modern Therapeutics","author":"Sawarkar","year":"2020"},{"key":"10.1016\/j.drudis.2024.103974_b0010","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.3389\/fmicb.2018.03158","article-title":"Principles of immunotherapy: implications for treatment strategies in cancer and infectious diseases","volume":"9","author":"Naran","year":"2018","journal-title":"Front Microbiol"},{"key":"10.1016\/j.drudis.2024.103974_b0015","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.3389\/fimmu.2017.01668","article-title":"The future of immunotherapy: a 20-year perspective","volume":"8","author":"Wraith","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.drudis.2024.103974_b0020","doi-asserted-by":"crossref","first-page":"250","DOI":"10.20517\/2394-4722.2017.41","article-title":"Cancer immunotherapy: a brief review of the history, possibilities, and challenges ahead","volume":"3","author":"Oiseth","year":"2017","journal-title":"J Cancer Metastasis Treat"},{"key":"10.1016\/j.drudis.2024.103974_b0025","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","article-title":"A guide to cancer immunotherapy: from T cell basic science to clinical practice","volume":"20","author":"Waldman","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.drudis.2024.103974_b0030","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1097\/00000441-190412740-00001","article-title":"The influence of complicating diseases upon leukaemia","volume":"127","author":"Dock","year":"1904","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.drudis.2024.103974_b0035","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/184291a0","article-title":"Effect of Bacillus Calmette-Guerin infection on transplanted tumours in the mouse","volume":"184","author":"Old","year":"1959","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2024.103974_b0040","doi-asserted-by":"crossref","first-page":"829","DOI":"10.3389\/fimmu.2017.00829","article-title":"Cancer immunotherapy: historical perspective of a clinical revolution and emerging preclinical animal models","volume":"8","author":"Decker","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.drudis.2024.103974_b0045","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/ni1102-991","article-title":"Cancer immunoediting: from immunosurveillance to tumor escape","volume":"3","author":"Dunn","year":"2002","journal-title":"Nat Immunol"},{"key":"10.1016\/j.drudis.2024.103974_b0050","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3389\/fonc.2018.00163","article-title":"Past, present, and future of rituximab-the world\u2019s first oncology monoclonal antibody therapy","volume":"8","author":"Pierpont","year":"2018","journal-title":"Front Oncol"},{"key":"10.1016\/j.drudis.2024.103974_b0055","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.bj.2019.09.002","article-title":"Immune checkpoint inhibitors win the 2018 Nobel Prize","volume":"42","author":"Huang","year":"2019","journal-title":"Biomed J"},{"key":"10.1016\/j.drudis.2024.103974_b0060","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/ncb1104-1054","article-title":"Cell biology of protein misfolding: the examples of Alzheimer\u2019s and Parkinson\u2019s diseases","volume":"6","author":"Selkoe","year":"2004","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.drudis.2024.103974_b0065","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1126\/science.1067122","article-title":"Toxic proteins in neurodegenerative disease","volume":"296","author":"Taylor","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.drudis.2024.103974_b0070","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.654739","article-title":"Immunotherapies for neurodegenerative diseases","volume":"12","author":"Mortada","year":"2021","journal-title":"Front Neurol"},{"key":"10.1016\/j.drudis.2024.103974_b0075","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.cell.2010.02.016","article-title":"Mechanisms underlying inflammation in neurodegeneration","volume":"140","author":"Glass","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2024.103974_b0080","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/jnc.14674","article-title":"Inflammatory mechanisms in neurodegeneration","volume":"149","author":"Nichols","year":"2019","journal-title":"J Neurochem"},{"key":"10.1016\/j.drudis.2024.103974_b0085","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/imm.12233","article-title":"Inflammation in neurodegenerative diseases\u2013an update","volume":"142","author":"Amor","year":"2014","journal-title":"Immunology"},{"key":"10.1016\/j.drudis.2024.103974_b0090","doi-asserted-by":"crossref","first-page":"850","DOI":"10.4103\/1673-5374.268971","article-title":"Neurodegenerative diseases as proteinopathies-driven immune disorders","volume":"15","author":"Ciccocioppo","year":"2020","journal-title":"Neural Regen Res"},{"key":"10.1016\/j.drudis.2024.103974_b0095","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/22124","article-title":"Immunization with amyloid-\u03b2 attenuates Alzheimer-disease-like pathology in the PDAPP mouse","volume":"400","author":"Schenk","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2024.103974_b0100","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/jnc.13632","article-title":"The amyloid cascade hypothesis: are we poised for success or failure?","volume":"139","author":"Karran","year":"2016","journal-title":"J Neurochem"},{"key":"10.1016\/j.drudis.2024.103974_b0105","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ebiom.2016.03.035","article-title":"The role of amyloid-\u03b2 oligomers in toxicity, propagation, and immunotherapy","volume":"6","author":"Sengupta","year":"2016","journal-title":"eBioMedicine"},{"key":"10.1016\/j.drudis.2024.103974_b0110","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/acel.12359","article-title":"The interrelationship of proteasome impairment and oligomeric intermediates in neurodegeneration","volume":"14","author":"Deger","year":"2015","journal-title":"Aging Cell"},{"key":"10.1016\/j.drudis.2024.103974_b0115","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1021\/acs.chemrev.0c01122","article-title":"Amyloid oligomers: a joint experimental\/computational perspective on Alzheimer\u2019s disease, Parkinson\u2019s disease, type II diabetes, and Amyotrophic lateral sclerosis","volume":"121","author":"Nguyen","year":"2021","journal-title":"Chem Rev"},{"key":"10.1016\/j.drudis.2024.103974_b0120","doi-asserted-by":"crossref","first-page":"4290","DOI":"10.1016\/j.molcel.2022.09.031","article-title":"Formation of toxic oligomers of polyQ-expanded Huntingtin by prion-mediated cross-seeding","volume":"82","author":"Gropp","year":"2022","journal-title":"Mol Cell"},{"key":"10.1016\/j.drudis.2024.103974_b0125","doi-asserted-by":"crossref","first-page":"3577","DOI":"10.1172\/JCI90609","article-title":"CNS inflammation and neurodegeneration","volume":"127","author":"Chitnis","year":"2017","journal-title":"J Clin Invest"},{"key":"10.1016\/j.drudis.2024.103974_b0130","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a009258","article-title":"Parkinson\u2019s disease and Parkinsonism: neuropathology","volume":"2","author":"Dickson","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.drudis.2024.103974_b0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2020.104760","article-title":"Immunotherapy for Parkinson\u2019s disease","volume":"137","author":"Schwab","year":"2020","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.drudis.2024.103974_b0140","doi-asserted-by":"crossref","first-page":"17013","DOI":"10.1038\/nrdp.2017.13","article-title":"Parkinson disease primer","volume":"3","author":"Poewe","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.drudis.2024.103974_b0145","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a009399","article-title":"\u03b1-Synuclein in Parkinson\u2019s disease","volume":"2","author":"Stefanis","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.drudis.2024.103974_b0150","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.bcp.2014.01.015","article-title":"Pathogenesis of synaptic degeneration in Alzheimer\u2019s disease and Lewy body disease","volume":"88","author":"Overk","year":"2014","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.drudis.2024.103974_b0155","first-page":"9","article-title":"The discovery of dopamine deficiency in the parkinsonian brain","volume":"70","author":"Hornykiewicz","year":"2006","journal-title":"J Neural Transm Suppl"},{"key":"10.1016\/j.drudis.2024.103974_b0160","doi-asserted-by":"crossref","first-page":"693","DOI":"10.3389\/fnins.2018.00693","article-title":"Emerging treatment approaches for Parkinson\u2019s disease","volume":"12","author":"Stoker","year":"2018","journal-title":"Front Neurosci"},{"key":"10.1016\/j.drudis.2024.103974_b0165","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1021\/acschemneuro.5b00158","article-title":"Understanding caffeine\u2019s role in attenuating the toxicity of \u03b1-synuclein aggregates: implications for risk of Parkinson\u2019s disease","volume":"6","author":"Kardani","year":"2015","journal-title":"ACS Chem Neurosci"},{"key":"10.1016\/j.drudis.2024.103974_b0170","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/WCO.0b013e3283632d08","article-title":"Deep brain stimulation for Parkinson\u2019s disease and other movement disorders","volume":"26","author":"Kalia","year":"2013","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.drudis.2024.103974_b0175","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.conb.2003.11.001","article-title":"Deep brain stimulation for Parkinson\u2019s disease","volume":"13","author":"Benabid","year":"2003","journal-title":"Curr Opin Neurobiol"},{"key":"10.1016\/j.drudis.2024.103974_b0180","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1474-4422(13)70293-X","article-title":"Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson\u2019s disease: a randomised, controlled, double-blind, double-dummy study","volume":"13","author":"Olanow","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.drudis.2024.103974_b0185","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/s41582-020-0344-4","article-title":"Parkinson disease and the immune system\u2014associations, mechanisms and therapeutics","volume":"16","author":"Tan","year":"2020","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.drudis.2024.103974_b0190","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/S1474-4422(09)70062-6","article-title":"Neuroinflammation in Parkinson\u2019s disease: a target for neuroprotection?","volume":"8","author":"Hirsch","year":"2009","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.drudis.2024.103974_b0195","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s12149-016-1099-2","article-title":"Extrastriatal spreading of microglial activation in Parkinson\u2019s disease: a positron emission tomography study","volume":"30","author":"Terada","year":"2016","journal-title":"Ann Nucl Med"},{"key":"10.1016\/j.drudis.2024.103974_b0200","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s40478-017-0494-9","article-title":"\u03b1-Synuclein fibrils recruit peripheral immune cells in the rat brain prior to neurodegeneration","volume":"5","author":"Harms","year":"2017","journal-title":"Acta Neuropathol Commun"},{"key":"10.1016\/j.drudis.2024.103974_b0205","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/0304-3940(96)12706-3","article-title":"Interleukin (IL)-1\u03b2, IL-2, IL-4, IL-6 and transforming growth factor-\u03b1 levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson\u2019s disease","volume":"211","author":"Mogi","year":"1996","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.drudis.2024.103974_b0210","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/nature11748","article-title":"Suppression of neuroinflammation by astrocytic dopamine D2 receptors via \u03b1B-crystallin","volume":"494","author":"Shao","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2024.103974_b0215","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s13075-023-03071-1","article-title":"Dopamine D2 receptor on CD4+ T cells is protective against inflammatory responses and signs in a mouse model of rheumatoid arthritis","volume":"25","author":"Wang","year":"2023","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.drudis.2024.103974_b0220","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neures.2018.01.002","article-title":"Comparative review of adult midbrain and striatum neurogenesis with classical neurogenesis","volume":"134","author":"Farzanehfar","year":"2018","journal-title":"Neurosci Res"},{"key":"10.1016\/j.drudis.2024.103974_b0225","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s40120-018-0122-z","article-title":"Emerging immunotherapies for Parkinson disease","volume":"8","author":"Zella","year":"2019","journal-title":"Neurol Ther"},{"key":"10.1016\/j.drudis.2024.103974_b0230","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13024-015-0008-9","article-title":"Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy","volume":"10","author":"Mandler","year":"2014","journal-title":"Mol Neurodegener"},{"key":"10.1016\/j.drudis.2024.103974_b0235","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.pharmthera.2013.01.013","article-title":"Immunotherapy for neurodegenerative diseases: focus on \u03b1-synucleinopathies","volume":"138","author":"Valera","year":"2013","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.drudis.2024.103974_b0240","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s40005-021-00521-3","article-title":"Development of immunotherapy and nanoparticles-based strategies for the treatment of Parkinson\u2019s disease","volume":"51","author":"Duwa","year":"2021","journal-title":"J Pharm Investig"},{"key":"10.1016\/j.drudis.2024.103974_b0245","doi-asserted-by":"crossref","first-page":"9441","DOI":"10.1523\/JNEUROSCI.5314-13.2014","article-title":"Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson\u2019s disease-like models","volume":"34","author":"Games","year":"2014","journal-title":"J Neurosci"},{"key":"10.1016\/j.drudis.2024.103974_b0250","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s40265-019-01104-1","article-title":"Targeting \u03b1-synuclein in Parkinson\u2019s disease: progress towards the development of disease-modifying therapeutics","volume":"79","author":"Savitt","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.drudis.2024.103974_b0255","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1002\/mds.27414","article-title":"Targeted therapies for Parkinson\u2019s disease: from genetics to the clinic","volume":"33","author":"Sardi","year":"2018","journal-title":"Mov Disord"},{"key":"10.1016\/j.drudis.2024.103974_b0260","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/mds.28808","article-title":"Genetic stratification of age-dependent Parkinson\u2019s disease risk by polygenic hazard score","volume":"37","author":"Pihlstr\u00f8m","year":"2022","journal-title":"Mov Disord"},{"key":"10.1016\/j.drudis.2024.103974_b0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2019.104587","article-title":"Immunotherapy in Parkinson\u2019s disease: current status and future directions","volume":"132","author":"Chatterjee","year":"2019","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.drudis.2024.103974_b0270","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S1474-4422(20)30136-8","article-title":"Safety and immunogenicity of the \u03b1-synuclein active immunotherapeutic PD01A in patients with Parkinson\u2019s disease: a randomised, single-blinded, phase 1 trial","volume":"19","author":"Volc","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.drudis.2024.103974_b0275","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1523\/JNEUROSCI.1170-17.2017","article-title":"Combined active humoral and cellular immunization approaches for the treatment of synucleinopathies","volume":"38","author":"Rockenstein","year":"2018","journal-title":"J Neurosci"},{"key":"10.1016\/j.drudis.2024.103974_b0280","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1080\/21645515.2015.1012033","article-title":"Evaluation of an \u03b1 synuclein sensitized dendritic cell based vaccine in a transgenic mouse model of Parkinson disease","volume":"11","author":"Ugen","year":"2015","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.drudis.2024.103974_b0285","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1007\/s10072-012-1284-6","article-title":"Immune effects of optimized DNA vaccine and protective effects in a MPTP model of Parkinson\u2019s disease","volume":"34","author":"Chen","year":"2013","journal-title":"Neurol Sci"},{"key":"10.1016\/j.drudis.2024.103974_b0290","doi-asserted-by":"crossref","first-page":"e19338","DOI":"10.1371\/journal.pone.0019338","article-title":"Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease","volume":"6","author":"Masliah","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.drudis.2024.103974_b0295","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s40478-016-0410-8","article-title":"Anti-\u03b1-synuclein immunotherapy reduces \u03b1-synuclein propagation in the axon and degeneration in a combined viral vector and transgenic model of synucleinopathy","volume":"5","author":"Spencer","year":"2017","journal-title":"Acta Neuropathol Commun"},{"key":"10.1016\/j.drudis.2024.103974_b0300","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/mds.26878","article-title":"First-in-human assessment of PRX002, an anti-\u03b1-synuclein monoclonal antibody, in healthy volunteers","volume":"32","author":"Schenk","year":"2017","journal-title":"Mov Dis"},{"key":"10.1016\/j.drudis.2024.103974_b0305","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1001\/jamaneurol.2018.1487","article-title":"Safety and tolerability of multiple ascending doses of PRX002\/RG7935, an anti\u2013\u03b1-synuclein monoclonal antibody, in patients with Parkinson disease: a randomized clinical trial","volume":"75","author":"Jankovic","year":"2018","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.drudis.2024.103974_b0310","doi-asserted-by":"crossref","first-page":"12081","DOI":"10.1038\/s41598-022-15874-4","article-title":"Reliability and validity of the Roche PD Mobile application for remote monitoring of early Parkinson\u2019s disease","volume":"12","author":"Lipsmeier","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.drudis.2024.103974_b0315","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1056\/NEJMoa2202867","article-title":"Trial of prasinezumab in early-stage Parkinson\u2019s disease","volume":"387","author":"Pagano","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2024.103974_b0320","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.nbd.2018.10.016","article-title":"Development of an aggregate-selective, human-derived \u03b1-synuclein antibody BIIB054 that ameliorates disease phenotypes in Parkinson\u2019s disease models","volume":"124","author":"Weihofen","year":"2019","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.drudis.2024.103974_b0325","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1002\/mds.27738","article-title":"Randomized phase I clinical trial of anti\u2013\u03b1-synuclein antibody BIIB054","volume":"34","author":"Brys","year":"2019","journal-title":"Mov Disord"},{"key":"10.1016\/j.drudis.2024.103974_b0330","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa2203395","article-title":"Trial of cinpanemab in early Parkinson\u2019s disease","volume":"387","author":"Lang","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2024.103974_b0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2019.104582","article-title":"Preclinical development of a high affinity \u03b1-synuclein antibody, MEDI1341, that can enter the brain, sequester extracellular \u03b1-synuclein and attenuate \u03b1-synuclein spreading in vivo","volume":"132","author":"Schofield","year":"2019","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.drudis.2024.103974_b0340","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000202579","article-title":"Reducing \u03b1-synuclein in human CSF; an evaluation of safety, tolerability, pharmacokinetics and pharmacodynamics of MEDI1341, an \u03b1-synuclein-specific antibody, in healthy volunteers and Parkinson\u2019s disease patients (P1\u201311.007)","volume":"100","author":"Shering","year":"2023","journal-title":"Neurology"},{"key":"10.1016\/j.drudis.2024.103974_b0345","first-page":"1598","article-title":"Alzheimer\u2019s disease facts and figures","volume":"19","author":"Alzheimer\u2019s Association","year":"2023","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.drudis.2024.103974_b0350","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0140-6736(20)32205-4","article-title":"Alzheimer\u2019s disease","volume":"397","author":"Scheltens","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2024.103974_b0355","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41467-019-08352-5","article-title":"PD-1\/PD-L1 checkpoint blockade harnesses monocyte-derived macrophages to combat cognitive impairment in a tauopathy mouse model","volume":"10","author":"Rosenzweig","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2024.103974_b0360","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00401-016-1662-x","article-title":"Alzheimer\u2019s disease: experimental models and reality","volume":"133","author":"Drummond","year":"2017","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.drudis.2024.103974_b0365","doi-asserted-by":"crossref","first-page":"595","DOI":"10.15252\/emmm.201606210","article-title":"The amyloid hypothesis of Alzheimer\u2019s disease at 25 years","volume":"8","author":"Selkoe","year":"2016","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.drudis.2024.103974_b0370","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.2174\/1871527315666161003165855","article-title":"Multiple targets for the management of Alzheimer\u2019s disease","volume":"15","author":"Ahmad","year":"2016","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"10.1016\/j.drudis.2024.103974_b0375","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/jnc.12715","article-title":"Function, therapeutic potential and cell biology of BACE proteases: current status and future prospects","volume":"130","author":"Vassar","year":"2014","journal-title":"J Neurochem"},{"key":"10.1016\/j.drudis.2024.103974_b0380","doi-asserted-by":"crossref","first-page":"203","DOI":"10.25100\/cm.v47i4.2640","article-title":"Amyloid-beta immunotherapy: the hope for Alzheimer disease?","volume":"47","author":"Barrera-Ocampo","year":"2016","journal-title":"Colombia Med"},{"key":"10.1016\/j.drudis.2024.103974_b0385","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1001\/jama.2022.24494","article-title":"Lecanemab gains FDA approval for early Alzheimer disease","volume":"329","author":"Larkin","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.drudis.2024.103974_b0390","doi-asserted-by":"crossref","first-page":"033","DOI":"10.24966\/AND-9608\/100033","article-title":"A framework for patient stratification in clinical trials for Alzheimer\u2019s disease","volume":"6","author":"Cousins","year":"2020","journal-title":"J Alzheimers Neurodegener Dis"},{"key":"10.1016\/j.drudis.2024.103974_b0395","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/S1474-4422(21)00066-1","article-title":"Clinical diagnosis of Alzheimer\u2019s disease: recommendations of the international working group","volume":"20","author":"Dubois","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.drudis.2024.103974_b0400","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S0140-6736(08)61075-2","article-title":"Long-term effects of A\u03b242 immunisation in Alzheimer\u2019s disease: follow-up of a randomised, placebo-controlled phase I trial","volume":"372","author":"Holmes","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2024.103974_b0405","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1212\/01.WNL.0000159740.16984.3C","article-title":"Clinical effects of A\u03b2 immunization (AN1792) in patients with AD in an interrupted trial","volume":"64","author":"Gilman","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.drudis.2024.103974_b0410","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1159\/000113700","article-title":"Progress in the active immunotherapeutic approach to Alzheimer\u2019s disease: clinical investigations into AN1792-associated meningoencephalitis","volume":"5","author":"Pride","year":"2008","journal-title":"Neurodegener Dis"},{"key":"10.1016\/j.drudis.2024.103974_b0415","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1093\/brain\/awz142","article-title":"Persistent neuropathological effects 14 years following amyloid-\u03b2 immunization in Alzheimer\u2019s disease","volume":"142","author":"Nicoll","year":"2019","journal-title":"Brain"},{"key":"10.1016\/j.drudis.2024.103974_b0420","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/ana.25410","article-title":"Amyloid-\u03b2 immunotherapy for Alzheimer disease: is it now a long shot?","volume":"85","author":"Panza","year":"2019","journal-title":"Ann Neurol"},{"key":"10.1016\/j.drudis.2024.103974_b0425","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1126\/science.1088469","article-title":"Immunotherapeutic approaches to Alzheimer\u2019s disease","volume":"302","author":"Monsonego","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.drudis.2024.103974_b0430","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.3233\/JAD-150376","article-title":"Two phase 2 multiple ascending\u2013dose studies of vanutidecridificar (ACC-001) and QS-21 adjuvant in mild-to-moderate Alzheimer\u2019s disease","volume":"51","author":"Pasquier","year":"2016","journal-title":"J Alzheimer\u2019s Dis"},{"key":"10.1016\/j.drudis.2024.103974_b0435","doi-asserted-by":"crossref","first-page":"9323","DOI":"10.1523\/JNEUROSCI.0293-11.2011","article-title":"The second-generation active A\u03b2 immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects","volume":"31","author":"Wiessner","year":"2011","journal-title":"J Neurosci"},{"key":"10.1016\/j.drudis.2024.103974_b0440","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1474-4422(12)70140-0","article-title":"Safety, tolerability, and antibody response of active A\u03b2 immunotherapy with CAD106 in patients with Alzheimer\u2019s disease: randomised, double-blind, placebo-controlled, first-in-human study","volume":"11","author":"Winblad","year":"2012","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.drudis.2024.103974_b0445","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.trci.2016.12.003","article-title":"Active A\u03b2 immunotherapy CAD106 in Alzheimer\u2019s disease: a phase 2b study","volume":"3","author":"Vandenberghe","year":"2017","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.drudis.2024.103974_b0450","first-page":"453","article-title":"Outreach, screening, and randomization of APOE \u03b54 carriers into an Alzheimer\u2019s prevention trial: a global perspective from the API generation program","volume":"10","author":"Walsh","year":"2023","journal-title":"J Prev Alzheimers Dis"},{"key":"10.1016\/j.drudis.2024.103974_b0455","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13195-018-0340-8","article-title":"Safety, tolerability and immunogenicity of an active anti-A\u03b2 40 vaccine (ABvac40) in patients with Alzheimer\u2019s disease: a randomised, double-blind, placebo-controlled, phase I trial","volume":"10","author":"Lacosta","year":"2018","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.drudis.2024.103974_b0460","doi-asserted-by":"crossref","first-page":"13966","DOI":"10.1074\/jbc.M110.186338","article-title":"Sequence-independent control of peptide conformation in liposomal vaccines for targeting protein misfolding diseases","volume":"286","author":"Hickman","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.drudis.2024.103974_b0465","doi-asserted-by":"crossref","first-page":"9810","DOI":"10.1073\/pnas.0703137104","article-title":"Liposomal vaccines with conformation-specific amyloid peptide antigens define immune response and efficacy in APP transgenic mice","volume":"104","author":"Muhs","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.drudis.2024.103974_b0470","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1001\/jamaneurol.2022.0983","article-title":"Safety, tolerability, and immunogenicity of the ACI-24 vaccine in adults with Down syndrome: a phase 1b randomized clinical trial","volume":"79","author":"Rafii","year":"2022","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.drudis.2024.103974_b0475","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcac022","article-title":"An amyloid beta vaccine that safely drives immunity to a key pathological species in Alzheimer\u2019s disease: pyroglutamate amyloid beta","volume":"4","author":"Vukicevic","year":"2022","journal-title":"Brain Commun"},{"key":"10.1016\/j.drudis.2024.103974_b0480","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.molmed.2015.03.003","article-title":"Tau immunotherapy for Alzheimer\u2019s disease","volume":"21","author":"Pedersen","year":"2015","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.drudis.2024.103974_b0485","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2020.108104","article-title":"Tau immunotherapies: lessons learned, current status and future considerations","volume":"175","author":"Sandusky-Beltran","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.drudis.2024.103974_b0490","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0072301","article-title":"Efficacy and safety of a liposome-based vaccine against protein Tau, assessed in tau. P301L mice that model tauopathy","volume":"8","author":"Theunis","year":"2013","journal-title":"PLoS One."},{"key":"10.1016\/j.drudis.2024.103974_b0495","doi-asserted-by":"crossref","first-page":"915","DOI":"10.3233\/JAD-140996","article-title":"N-terminal truncation of microtubule-associated protein tau dysregulates its cellular localization","volume":"43","author":"Paholikova","year":"2015","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.drudis.2024.103974_b0500","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/alzrt278","article-title":"First-in-man tau vaccine targeting structural determinants essential for pathological tau\u2013tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer\u2019s disease model","volume":"6","author":"Kontsekova","year":"2014","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.drudis.2024.103974_b0505","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1517\/13543784.2015.1075002","article-title":"Early investigational drugs targeting tau protein for the treatment of Alzheimer\u2019s disease","volume":"24","author":"Anand","year":"2015","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.drudis.2024.103974_b0510","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/s43587-021-00070-2","article-title":"ADAMANT: a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer\u2019s disease","volume":"1","author":"Novak","year":"2021","journal-title":"Nat Aging"},{"key":"10.1016\/j.drudis.2024.103974_b0515","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.xphs.2019.10.024","article-title":"Passive immunotherapies targeting amyloid beta and tau oligomers in Alzheimer\u2019s disease","volume":"109","author":"Vander Zanden","year":"2020","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.drudis.2024.103974_b0520","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13024-018-0298-9","article-title":"New insights into the role of TREM2 in Alzheimer\u2019s disease","volume":"13","author":"Gratuze","year":"2018","journal-title":"Mol Neurodegener"},{"key":"10.1016\/j.drudis.2024.103974_b0525","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1084\/jem.194.8.1111","article-title":"A DAP12-mediated pathway regulates expression of CC chemokine receptor 7 and maturation of human dendritic cells","volume":"194","author":"Bouchon","year":"2001","journal-title":"J Exp Med"},{"key":"10.1016\/j.drudis.2024.103974_b0530","doi-asserted-by":"crossref","first-page":"e20200785","DOI":"10.1084\/jem.20200785","article-title":"Anti-human TREM2 induces microglia proliferation and reduces pathology in an Alzheimer\u2019s disease model","volume":"217","author":"Wang","year":"2020","journal-title":"J Exp Med"},{"key":"10.1016\/j.drudis.2024.103974_b0535","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.jalz.2011.05.2351","article-title":"Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer\u2019s association research roundtable workgroup","volume":"7","author":"Sperling","year":"2011","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.drudis.2024.103974_b0540","doi-asserted-by":"crossref","first-page":"e230009","DOI":"10.1148\/rg.230009","article-title":"Amyloid-related imaging abnormalities in Alzheimer disease treated with anti-amyloid-\u03b2 therapy","volume":"43","author":"Agarwal","year":"2023","journal-title":"Radiographics"},{"key":"10.1016\/j.drudis.2024.103974_b0545","first-page":"416","article-title":"A TREM2-activating antibody with a blood\u2013brain barrier transport vehicle enhances microglial metabolism in Alzheimer\u2019s disease models","volume":"26","author":"vanLengerich","year":"2023","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.drudis.2024.103974_b0550","doi-asserted-by":"crossref","first-page":"e20220654","DOI":"10.1084\/jem.20220654","article-title":"Chronic TREM2 activation exacerbates A\u03b2-associated tau seeding and spreading","volume":"220","author":"Jain","year":"2023","journal-title":"J Exp Med"},{"key":"10.1016\/j.drudis.2024.103974_b0555","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1056\/NEJMoa2310168","article-title":"Biomarker changes during 20 years preceding Alzheimer\u2019s disease","volume":"390","author":"Jia","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2024.103974_b0560","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1038\/s41587-023-01936-z","article-title":"Drugs catch a ride through the blood\u2013brain barrier","volume":"41","author":"Sheridan","year":"2023","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.drudis.2024.103974_b0565","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s40035-022-00292-3","article-title":"Immunotherapy for Alzheimer\u2019s disease: targeting \u03b2-amyloid and beyond","volume":"11","author":"Song","year":"2022","journal-title":"Transl Neurodegener"},{"key":"10.1016\/j.drudis.2024.103974_b0570","doi-asserted-by":"crossref","first-page":"11495","DOI":"10.1523\/JNEUROSCI.3697-05.2005","article-title":"IgG-assisted age-dependent clearance of Alzheimer\u2019s amyloid \u03b2 peptide by the blood\u2013brain barrier neonatal Fc receptor","volume":"25","author":"Deane","year":"2005","journal-title":"J Neurosci"},{"key":"10.1016\/j.drudis.2024.103974_b0575","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/mp.2008.96","article-title":"Clearance mechanisms of Alzheimer\u2019s amyloid-\u03b2 peptide: implications for therapeutic design and diagnostic tests","volume":"14","author":"Bates","year":"2009","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.drudis.2024.103974_b0580","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1056\/NEJMoa2305032","article-title":"Trial of solanezumab in preclinical Alzheimer\u2019s Disease","volume":"389","author":"Sperling","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2024.103974_b0585","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1001\/archneurol.2011.1538","article-title":"Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab","volume":"69","author":"Ostrowitzki","year":"2012","journal-title":"Arch Neurol"},{"key":"10.1016\/j.drudis.2024.103974_b0590","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.neuron.2013.10.061","article-title":"Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle","volume":"81","author":"Niewoehner","year":"2014","journal-title":"Neuron"},{"key":"10.1016\/j.drudis.2024.103974_b0595","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.neuron.2012.10.029","article-title":"A plaque-specific antibody clears existing \u03b2-amyloid plaques in Alzheimer\u2019s disease mice","volume":"76","author":"DeMattos","year":"2012","journal-title":"Neuron"},{"key":"10.1016\/j.drudis.2024.103974_b0600","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","article-title":"Donanemab in early Alzheimer\u2019s disease","volume":"384","author":"Mintun","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2024.103974_b0605","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1002\/cpt.2875","article-title":"Donanemab population pharmacokinetics, amyloid plaque reduction and safety in participants with Alzheimer\u2019s disease","volume":"113","author":"Gueorguieva","year":"2023","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.drudis.2024.103974_b0610","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer Disease: the TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.drudis.2024.103974_b0615","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1001\/jamainternmed.2022.1039","article-title":"What to know about the Alzheimer drug aducanumab (Aduhelm)","volume":"182","author":"Woloshin","year":"2022","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.drudis.2024.103974_b0620","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature19323","article-title":"The antibody aducanumab reduces A\u03b2 plaques in Alzheimer\u2019s disease","volume":"537","author":"Sevigny","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2024.103974_b0625","doi-asserted-by":"crossref","first-page":"575","DOI":"10.3233\/JAD-140741","article-title":"The murine version of BAN2401 (mAb158) selectively reduces amyloid-\u03b2 protofibrils in brain and cerebrospinal fluid of tg-ArcSwe mice","volume":"43","author":"Tucker","year":"2015","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.drudis.2024.103974_b0630","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1212\/WNL.0000000000207505","article-title":"Lecanemab: looking before we leap","volume":"101","author":"Burke","year":"2023","journal-title":"Neurology"},{"key":"10.1016\/j.drudis.2024.103974_b0635","doi-asserted-by":"crossref","first-page":"P326","DOI":"10.1016\/j.jalz.2013.04.166","article-title":"ACU-193: a candidate therapeutic antibody that selectively targets soluble beta-amyloid oligomers","volume":"9","author":"Krafft","year":"2013","journal-title":"Alzheimer\u2019s Dement"},{"key":"10.1016\/j.drudis.2024.103974_b0640","doi-asserted-by":"crossref","first-page":"4634","DOI":"10.1038\/s41598-018-22979-2","article-title":"An acute functional screen identifies an effective antibody targeting amyloid-\u03b2 oligomers based on calcium imaging","volume":"8","author":"Wang","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.drudis.2024.103974_b0645","doi-asserted-by":"crossref","first-page":"P595","DOI":"10.1016\/j.jalz.2019.06.2470","article-title":"Soluble A\u03b2-oligomer\u2013selective antibody ACU-3B3 reduces amyloid pathology and improves multiple behavioral domains in a mouse model of Alzheimer\u2019s disease","volume":"15","author":"Ma","year":"2019","journal-title":"Alzheimer\u2019s Dement"},{"key":"10.1016\/j.drudis.2024.103974_b0650","doi-asserted-by":"crossref","first-page":"e12087","DOI":"10.1002\/trc2.12087","article-title":"A\u03b2 oligomer induced cognitive impairment and evaluation of ACU193-MNS-based MRI in rabbit","volume":"6","author":"Rozema","year":"2020","journal-title":"Alzheimer\u2019s Dement Transl Res Clin Interv"},{"key":"10.1016\/j.drudis.2024.103974_b0655","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1038\/78682","article-title":"Peripherally administered antibodies against amyloid \u03b2-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease","volume":"6","author":"Bard","year":"2000","journal-title":"Nat Med"},{"key":"10.1016\/j.drudis.2024.103974_b0660","doi-asserted-by":"crossref","first-page":"557","DOI":"10.3233\/JAD-160216","article-title":"Central review of amyloid-related imaging abnormalities in two phase III clinical trials of bapineuzumab in mild-to-moderate Alzheimer\u2019s disease patients","volume":"57","author":"Ketter","year":"2017","journal-title":"J Alzheimer\u2019s Dis"},{"key":"10.1016\/j.drudis.2024.103974_b0665","doi-asserted-by":"crossref","first-page":"9096","DOI":"10.1523\/JNEUROSCI.1697-05.2005","article-title":"\u03b2-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer\u2019s disease","volume":"25","author":"Buttini","year":"2005","journal-title":"J Neurosci"},{"key":"10.1016\/j.drudis.2024.103974_b0670","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/nm1782","article-title":"Amyloid-\u03b2 protein dimers isolated directly from Alzheimer\u2019s brains impair synaptic plasticity and memory","volume":"14","author":"Shankar","year":"2008","journal-title":"Nat Med"},{"key":"10.1016\/j.drudis.2024.103974_b0675","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa1304839","article-title":"Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer\u2019s disease","volume":"370","author":"Salloway","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2024.103974_b0680","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.cell.2012.02.016","article-title":"Proline isomer-specific antibodies reveal the early pathogenic tau conformation in Alzheimer\u2019s disease","volume":"149","author":"Nakamura","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2024.103974_b0685","doi-asserted-by":"crossref","first-page":"8646","DOI":"10.1038\/s41598-019-45234-8","article-title":"Traumatic brain injury-related voiding dysfunction in mice is caused by damage to rostral pathways, altering inputs to the reflex pathways","volume":"9","author":"Albayram","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.drudis.2024.103974_b0690","doi-asserted-by":"crossref","first-page":"5407","DOI":"10.1002\/alz.13128","article-title":"APOE \u03b54's impact on response to amyloid therapies in early symptomatic Alzheimer\u2019s disease: analyses from multiple clinical trials","volume":"19","author":"Evans","year":"2023","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.drudis.2024.103974_b0695","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2023.102012","article-title":"Efficacy and safety of anti-amyloid-\u03b2 monoclonal antibodies in current Alzheimer\u2019s disease Phase III clinical trials: a systematic review and interactive web app-based meta-analysis","volume":"90","author":"Jeremic","year":"2023","journal-title":"Ageing Res Rev"},{"key":"10.1016\/j.drudis.2024.103974_b0700","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S1474-4422(14)70090-0","article-title":"Advancing research diagnostic criteria for Alzheimer\u2019s disease: the IWG-2 criteria","volume":"13","author":"Dubois","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.drudis.2024.103974_b0705","doi-asserted-by":"crossref","first-page":"e47739","DOI":"10.1371\/journal.pone.0047739","article-title":"Alzheimer\u2019s disease neuroimaging initiative: enrichment and stratification for predementia Alzheimer disease in clinical trials","volume":"7","author":"Holland","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.drudis.2024.103974_b0710","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1038\/s41593-018-0235-9","article-title":"Protein misfolding, aggregation, and conformational strains in neurodegenerative diseases","volume":"21","author":"Soto","year":"2018","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.drudis.2024.103974_b0715","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1146\/annurev-biochem-061516-045049","article-title":"Propagation of protein aggregation in neurodegenerative diseases","volume":"88","author":"Vaquer-Alicea","year":"2019","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.drudis.2024.103974_b0720","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s13311-020-00853-2","article-title":"Immunotherapies for aging-related neurodegenerative diseases-emerging perspectives and new targets","volume":"17","author":"Kwon","year":"2020","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.drudis.2024.103974_b0725","doi-asserted-by":"crossref","first-page":"e0345822","DOI":"10.1128\/spectrum.03458-22","article-title":"Predicting neurodegenerative disease using prepathology gut microbiota composition: a longitudinal study in mice modeling Alzheimer\u2019s disease pathologies","volume":"11","author":"Borsom","year":"2023","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.drudis.2024.103974_b0730","doi-asserted-by":"crossref","first-page":"7967","DOI":"10.1038\/ncomms8967","article-title":"Breaking immune tolerance by targeting Foxp3+ regulatory T cells mitigates Alzheimer\u2019s disease pathology","volume":"6","author":"Baruch","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2024.103974_b0735","doi-asserted-by":"crossref","first-page":"eadg4122","DOI":"10.1126\/scitranslmed.adg4122","article-title":"A protein panel in cerebrospinal fluid for diagnostic and predictive assessment of Alzheimer\u2019s disease","volume":"15","author":"Haque","year":"2023","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.drudis.2024.103974_b0740","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1016\/j.neuron.2022.09.007","article-title":"The brain-immune ecosystem: implications for immunotherapy in defeating neurodegenerative diseases","volume":"110","author":"Schwartz","year":"2022","journal-title":"Neuron"},{"key":"10.1016\/j.drudis.2024.103974_b0745","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1021\/acsnano.1c08120","article-title":"Smart nanomedicine to enable crossing blood\u2013brain barrier delivery of checkpoint blockade antibody for immunotherapy of glioma","volume":"16","author":"Wang","year":"2022","journal-title":"ACS Nano"},{"key":"10.1016\/j.drudis.2024.103974_b0750","doi-asserted-by":"crossref","first-page":"183ra57","DOI":"10.1126\/scitranslmed.3005338","article-title":"Addressing safety liabilities of TfR bispecific antibodies that cross the blood-brain barrier","volume":"5","author":"Couch","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.drudis.2024.103974_b0755","doi-asserted-by":"crossref","first-page":"5053","DOI":"10.1038\/s41467-023-40681-4","article-title":"CD98hc is a target for brain delivery of biotherapeutics","volume":"14","author":"Chew","year":"2023","journal-title":"Nat Commun"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644624000990?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644624000990?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T18:54:47Z","timestamp":1714503287000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644624000990"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":151,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S1359644624000990"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2024.103974","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunotherapy: An emerging treatment option for neurodegenerative diseases","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2024.103974","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103974"}}